Pharmacist-guided pre-emptive pharmacogenetic testing in antidepressant therapy (PrePGx): study protocol for an open-label, randomized controlled trial

BACKGROUND: It is known that only 50% of patients diagnosed with major depressive disorders (MDD) respond to the first-line antidepressant treatment. Accordingly, there is a need to improve response rates to reduce healthcare costs and patient suffering. One approach to increase rates of treatment r...

Descripción completa

Detalles Bibliográficos
Autores principales: Stäuble, Céline K., Lampert, Markus L., Allemann, Samuel, Hatzinger, Martin, Hersberger, Kurt E., Meyer zu Schwabedissen, Henriette E., Imboden, Christian, Mikoteit, Thorsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670138/
https://www.ncbi.nlm.nih.gov/pubmed/34906208
http://dx.doi.org/10.1186/s13063-021-05724-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670138/
https://www.ncbi.nlm.nih.gov/pubmed/34906208
http://dx.doi.org/10.1186/s13063-021-05724-5

Ejemplares similares